Global Product Management Intern @ QuidelOrtho

The Opportunity

QuidelOrtho unites the strengths of Quidel Corporation and Ortho Clinical Diagnostics, creating a world-leading in vitro diagnostics company with award-winning expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine. We are more than 6,000 strong and do business in over 130 countries, providing answers with fast, accurate and consistent testing where and when they are needed most – home to hospital, lab to clinic.

Our culture puts our team members first and prioritizes actions that support happiness, inspiration and engagement. We strive to build meaningful connections with each other as we believe that employee happiness and business success are linked. Join us in our mission to transform the power of diagnostics into a healthier future for all.

The Role

QuidelOrtho is looking for a Global Product Management Intern that wants to spend their summer of 2026 working towards our mission: Advancing the power of diagnostics for a healthier future for all. Interns will have the opportunity to gain knowledge and develop their skills all while contributing to key company projects and initiatives. Our team will help students apply their educational background and broaden their knowledge base within their role and learn more about working in the medical device/biotech industry. Interns will work with a mentor(s) on a guided and impactful project and will be able to collaborate with and be part of a supportive and dedicated team.

Our team manages a diverse portfolio of body fluid tests that impact the lives of over 600,000 patients worldwide every day. We are looking for a motivated intern to support strategic growth initiatives by identifying high-impact opportunities for product line expansion and conducting data analysis to better understand market trends and business forecasting.

In this role, you will collaborate with a cross-functional team in a fast-paced, global environment, gaining hands-on experience in strategic marketing, business insights, and portfolio management within a leading diagnostic company. Your contributions will help shape key decisions that drive medical and commercial impact.

This position is available in Rochester, NY, or remotely based on candidate qualifications.

This Internship is a full-time (40 hours per week) paid program for 10-12 weeks.

Session 1: June 15th through August 15th

Session 2: July 6th through September 21st

The Responsibilities

Market Research & Strategy: Analyze product-level market trends, identify emerging disease areas, and assess opportunities for new test development.
Product & Marketing Support: Collaborate with cross-functional teams to develop and refine product and marketing strategies.
Sales & Commercial Enablement: Enhance global sales efforts by improving templates, tools and marketing collateral.
Data Analysis & Forecasting: Perform data mining, spreadsheet analysis, and develop analytical models to track customer adoption and usage of new products.
Training & Communication: Assist in creating training content, selling tools, and marketing materials to support key products.
This role offers hands-on experience in a dynamic, global environment, allowing to develop critical skills in market analysis, strategic planning, and commercial execution within a leading diagnostic company.
Perform other work-related duties as assigned.

Job Deliverables

Research & Strategic Insights: Develop reports, tools, or templates that provide actionable insights for business growth.

New Product Opportunities: Present strategic recommendations for potential new product candidates.

Market & Business Analysis: Identify and communicate key business trends through data analysis.

Forecasting & Predictive Models: Create reusable analytical models to predict customer adoption of new products.

Sales & Marketing Optimization: Improve response tools to enhance global sales effectiveness.

Project Contributions: Deliver meaningful outputs from special projects.

The intern will present a PowerPoint presentation on his/her work to a cross-functional group.

The Individual

Required:

Must be currently enrolled as a full-time student in a Bachelor’s or Master’s program – Business Administration
Strong analytical skills with experience in data analysis, market research, or business intelligence
Excellent communication and presentation skills
Ability to work collaboratively in a cross-functional, global environment
Proficiency in Microsoft Excel and PowerPoint; experience with data visualization tools is a plus.
Project management and organizational skills and the ability to manage to tight deadlines
Background in Life Sciences and/or Biology
Must have work authorization in the United States at the time of hire and maintain ongoing work authorization during employment.

Preferred:

Prior internship or project experience in marketing, product management, or healthcare industry preferred

Self-motivated and proactive with the ability to take ownership of tasks.

The Work Environment

No strenuous physical activity, though occasional light lifting of files and related materials is required. 30% of time in meetings, working with team, or talking on the phone, 70% of the time at the desk on computer, doing analytical work.

Salary Transparency

The salary range for this position takes into account a wide range of factors including education, experience, knowledge, skills, geography, and abilities of the candidate, in addition to internal equity and alignment with market data. The salary range for current Junior, rising senior is $23.00/hour to $26.00/hour; Senior, enrolled in school for fall 2026 is $25.00/hour to $28.00/hour; or currently enrolled Graduate, MBD, PhD program is $28.00/hour to $30.00/hour. At QuidelOrtho, compensation decisions are dependent on the facts and circumstances of each case.

Equal Opportunity

QuidelOrtho believes in Equal Opportunity for all and is committed to ensuring all individuals, including individuals with disabilities, have an opportunity to apply for those positions that they are interested in and qualify for without regard to race, religion, color, national origin, citizenship, sex, sexual orientation, gender identity, age, veteran status, disability, genetic information, or any other protected characteristic. QuidelOrtho is also committed to providing reasonable accommodations to qualified individuals so that an individual can perform the duties. If you are interested in applying for an employment opportunity and require special assistance or an accommodation to apply due to a disability, please contact us at [email protected].

#LI-AC1 #LI-Remote

About the company

QuidelOrtho provides in vitro diagnostics (IVD) products, including diagnostic tests and equipment that use immunoassay and molecular testing to detect medical conditions. Its products are used in point-of-care settings, clinical laboratories, and transfusion medicine, serving individual healthcare providers to large institutions. The company develops and manufactures these tests and devices, which run on specialized platforms or point-of-care instruments to analyze patient samples and deliver quick, accurate results. What sets QuidelOrtho apart is its long history and the combination of Quidel’s and Ortho’s expertise into a broad portfolio, with a global reach and long-term contracts with healthcare providers. The company’s goal is to improve diagnostic accuracy and efficiency to support better patient outcomes and broad access to essential diagnostic solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, CA

Founded

1937

Get referred to QuidelOrtho

See people who can refer or advise you

Simplify's Take

What believers are saying

LEX launch later in 2026 adds a high-growth point-of-care molecular product.
Ex-China revenue grew 6% constant currency in Q2 2026, showing core franchise resilience.
Cost actions target $50 million net savings through 2027, supporting margin expansion.

What critics are saying

China's IVD pricing guidelines crushed Q2 2026 revenue 23.3% and guide cuts persist.
Free cash flow guidance was withdrawn after Q2 2026; deleveraging slips if China worsens.
A $2.8 billion debt load and B+ negative outlook leave bankruptcy risk if execution fails.

What makes QuidelOrtho unique

QuidelOrtho's LEX VELO, acquired April 2026, delivers PCR results in six minutes.
Its immunoassay, molecular, and transfusion platforms span point-of-care through hospital laboratories.
VITROS 450 and high-sensitivity troponin broaden a sticky installed base across care settings.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Employee Assistance Program

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

PR Newswire

Oct 7th, 2026

QuidelOrtho appoints Sanjeev Sharma as VP of investor relations

QuidelOrtho Corporation has appointed Sanjeev Sharma as Vice President of Investor Relations, effective 28 September 2026. Sharma brings over 20 years of experience in investor relations, corporate strategy, and equity research. Most recently, he served as Senior Director of Investor Relations at Teva Pharmaceuticals. He previously spent more than a decade at Genpact in investor relations and business strategy roles, and nearly six years in sell-side equity research. Sharma holds a master's degree in finance and is a Chartered Financial Analyst. QuidelOrtho is a global provider of diagnostic solutions with expertise spanning clinical chemistry, immunoassay, immunohematology, and molecular testing.

Market Chameleon

Oct 7th, 2026

QuidelOrtho taps a 20-year IR veteran to lead shareholder communications.

QuidelOrtho taps a 20-year IR veteran to lead shareholder communications. 7 October 2026, 11:58 AM Leadership change centers on "sharpening communications" with a newly appointed VP of Investor Relations. QuidelOrtho Corporation (NASDAQ:QDEL) announced the appointment of Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective September 28, 2026. The company said Sharma brings more than 20 years of experience spanning investor relations, corporate strategy, and equity research at global organizations. In the press release, Chief Financial Officer Micah Young highlighted Sharma's combination of investor relations leadership, healthcare experience, financial expertise, and capital markets perspective, describing it as especially valuable as QuidelOrtho works to "sharpen our communications and deepen our engagement with shareholders and analysts." Sharma's background blends healthcare IR and sell-side research experience. QuidelOrtho pointed to Sharma's most recent role as Senior Director of Investor Relations at Teva Pharmaceuticals, where he worked with senior leadership to communicate strategy and strengthen engagement with the investment community "during a period of significant transformation." Before Teva, he spent more than a decade at Genpact in progressively senior roles across investor relations and business strategy, and earlier in his career he spent nearly six years in sell-side equity research.

Spot On New Jersey

Oct 6th, 2026

Another biz flees Sherrill's New Jersey: QuidelOrtho plans 2027 closure of longtime Raritan facility.

Another biz flees Sherrill's New Jersey: QuidelOrtho plans 2027 closure of longtime Raritan facility. RARITAN, N.J. - Another longtime New Jersey business facility is heading for the exits. QuidelOrtho plans to close its 66-acre Route 202 campus in Raritan [...] |!| Raritan

MarketBeat

Sep 24th, 2026

QuidelOrtho (NASDAQ:QDEL) shares up 4.3% - time to buy?

QuidelOrtho (NASDAQ:QDEL) shares up 4.3% - time to buy? September 24, 2026 Key points. * QuidelOrtho shares rose 4.3% to about $10.79, though trading volume was 96% below the average session volume. * Analyst sentiment remains negative: the stock has a consensus rating of "Reduce", with three Holds and three Sells and an average price target of $13.62. * The company exceeded quarterly earnings and revenue estimates, reporting $0.13 EPS and $630.9 million in revenue, but continues to post a negative net margin; institutional investors own approximately 99% of the shares. * MarketBeat previews the top five stocks to own by October 1st. QuidelOrtho Corporation (NASDAQ:QDEL - Get Free Report) shares rose 4.3% during trading on Thursday. The stock traded as high as $10.77 and last traded at $10.7860. 68,206 shares traded hands during trading, a decline of 96% from the average session volume of 1,711,570 shares. The stock had previously closed at $10.34. Analysts set new price targets. A number of research firms have recently weighed in on QDEL. Weiss Ratings restated a "sell (e+)" rating on shares of QuidelOrtho in a report on Friday, July 17th. Zacks Research cut shares of QuidelOrtho from a "hold" rating to a "strong sell" rating in a report on Wednesday, August 12th. Jefferies Financial Group reissued a "hold" rating on shares of QuidelOrtho in a research report on Monday, June 29th. JPMorgan Chase & Co. raised their target price on QuidelOrtho from $11.00 to $12.00 and gave the company an "underweight" rating in a report on Wednesday, July 1st. Finally, Citigroup boosted their price target on QuidelOrtho from $13.00 to $18.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 8th. Three research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Reduce" and a consensus target price of $13.62. QuidelOrtho price performance. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76. The stock's 50 day moving average price is $14.42 and its two-hundred day moving average price is $14.53. The firm has a market capitalization of $728.27 million, a price-to-earnings ratio of -0.69 and a beta of 0.68. QuidelOrtho (NASDAQ:QDEL - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.18. The business had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. QuidelOrtho's revenue was up 2.8% compared to the same quarter last year. During the same period last year, the business posted $0.12 EPS. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. On average, equities research analysts anticipate that QuidelOrtho Corporation will post 0.75 EPS for the current year. Hedge funds weigh in on QuidelOrtho. A number of institutional investors have recently made changes to their positions in QDEL. BlackRock Inc. bought a new stake in QuidelOrtho during the 2nd quarter valued at approximately $196,212,000. Newtyn Management LLC lifted its holdings in shares of QuidelOrtho by 45.3% during the second quarter. Newtyn Management LLC now owns 6,625,000 shares of the company's stock worth $116,037,000 after buying an additional 2,066,528 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of QuidelOrtho by 7.5% during the first quarter. Dimensional Fund Advisors LP now owns 3,048,768 shares of the company's stock worth $50,085,000 after buying an additional 212,481 shares during the last quarter. Paradigm Capital Management Inc. NY bought a new stake in shares of QuidelOrtho in the second quarter valued at approximately $44,168,000. Finally, Private Management Group Inc. boosted its position in shares of QuidelOrtho by 49.5% in the second quarter. Private Management Group Inc. now owns 2,070,391 shares of the company's stock valued at $36,263,000 after acquiring an additional 685,622 shares during the period. 99.00% of the stock is currently owned by institutional investors. QuidelOrtho company profile. QuidelOrtho Corporation NASDAQ: QDEL develops, manufactures and distributes diagnostic products and solutions used to detect and monitor disease. The company serves hospitals, clinical laboratories, physician offices, retail clinics, blood banks and other healthcare providers worldwide. Discover more Market Data Access Research tools access EV Market Report Its portfolio includes point-of-care and molecular testing systems, immunoassays, clinical chemistry and immunodiagnostic platforms, and transfusion medicine products. Key product lines include the Sofia and QuickVue systems from Quidel and the VITROS, ORTHO Vision and ORTHO Workstation platforms from Ortho Clinical Diagnostics. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider QuidelOrtho, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QuidelOrtho wasn't on the list. While QuidelOrtho currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important. Continue following MarketBeat

Yahoo Finance

Aug 17th, 2026

QuidelOrtho rallies 31.7% despite China slowdown and slashed 2026 guidance

QuidelOrtho Corporation has risen 31.7% over three months, but faces headwinds that may limit further gains. The diagnostics company reported second-quarter revenues of $630.9 million, up 2.8% year over year, with Labs, Immunohematology and Point of Care segments all posting growth. Excluding China, revenues grew 6% at constant currency. Adjusted EBITDA increased 21% to $129 million, reaching a 20.5% margin, supported by ongoing cost optimisation efforts targeting $50 million in net savings through 2027. However, China revenues fell 23.3% at constant currency due to distributor inventory reductions ahead of pricing changes. Management expects these challenges to persist through 2026. QuidelOrtho lowered its full-year revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and cut adjusted earnings guidance to 65-90 cents per share from $1.80-$2.00, citing China weakness and conservative respiratory season assumptions.

QuidelOrtho

Global Product Management Intern

About the job